Primary Aldosteronism In Hypertensive Patients in China
NCT ID: NCT03155139
Last Updated: 2020-10-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
3500 participants
OBSERVATIONAL
2017-06-03
2018-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevalence of Primary Aldosteronism in Patients With Resistant Hypertension in China
NCT01459042
Chongqing Primary Aldosteronism Study
NCT03224312
Effect of Anti-hypertensive Medications on the Diagnostic Accuracy in Primary Aldosteronism
NCT04991961
Screening for Primary Aldosteronism in a Population of Patients With Hypertension
NCT03105531
Primary Aldosteronism: Prospective Screening Registry in China
NCT04020783
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
ECOLOGIC_OR_COMMUNITY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients without primary aldosteronism (PA)
PA case detection or confirmatory tests was negative.
Aldosterone/renin ratio (ARR) testing
Plasma aldosterone concentration tests, Direct renin concentration tests
Patients with primary aldosteronism (PA)
PA case detection and confirmatory tests were positive.
Aldosterone/renin ratio (ARR) testing
Plasma aldosterone concentration tests, Direct renin concentration tests
Confirmatory tests
Captopril challenge test, Saline infusion test
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aldosterone/renin ratio (ARR) testing
Plasma aldosterone concentration tests, Direct renin concentration tests
Confirmatory tests
Captopril challenge test, Saline infusion test
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Drug negative, or voluntary to discontinue/change the anti-hypertensive medications;
3. Aged between 18-80 year, gender is not limited;
4. Voluntary to sign on the informed consent.
Exclusion Criteria
2. suspicious or confirmed other types of secondary hypertension, including Cushing's syndrome, pheochromocytoma and renal artery stenosis.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fu Wai Hospital, Beijing, China
OTHER
Qifu Li
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Qifu Li
Primary Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jun Cai, phD
Role: PRINCIPAL_INVESTIGATOR
Hypertension Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease of China
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Li X, Goswami R, Yang S, Li Q. Aldosterone/direct renin concentration ratio as a screening test for primary aldosteronism: A meta-analysis. J Renin Angiotensin Aldosterone Syst. 2016 Aug 17;17(3):1470320316657450. doi: 10.1177/1470320316657450. Print 2016 Jul.
Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016 May;101(5):1889-916. doi: 10.1210/jc.2015-4061. Epub 2016 Mar 2.
Kayser SC, Dekkers T, Groenewoud HJ, van der Wilt GJ, Carel Bakx J, van der Wel MC, Hermus AR, Lenders JW, Deinum J. Study Heterogeneity and Estimation of Prevalence of Primary Aldosteronism: A Systematic Review and Meta-Regression Analysis. J Clin Endocrinol Metab. 2016 Jul;101(7):2826-35. doi: 10.1210/jc.2016-1472. Epub 2016 May 12.
Xu Z, Yang J, Hu J, Song Y, He W, Luo T, Cheng Q, Ma L, Luo R, Fuller PJ, Cai J, Li Q, Yang S; Chongqing Primary Aldosteronism Study (CONPASS) Group. Primary Aldosteronism in Patients in China With Recently Detected Hypertension. J Am Coll Cardiol. 2020 Apr 28;75(16):1913-1922. doi: 10.1016/j.jacc.2020.02.052.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PA-China 2017
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.